Galsulfase · NAGLAZYME

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Mucopolysaccharidosis Type VI

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
JP
  • Mucopolysaccharidosis VI (MPS VI)
Product first approved 2008biomarin.com
EU
  • Long-term enzyme-replacement therapy in confirmed MPS VI (Maroteaux-Lamy)
Product first approved 2006EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT00104234 · BioMarin Pharmaceutical
2004-02 – 2006-10 · Mucopolysaccharidosis VI
What this study did
Phase 4 (1)
Other / comorbidity
NCT00299000 · BioMarin Pharmaceutical
2006-05 – 2009-04 · Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02156674 · Masonic Cancer Center, University of Minnesota
2016-01-26 – 2019-12-01 · Maroteaux-Lamy Syndrome
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.